[go: up one dir, main page]

US20160041145A1 - Detection And Quantification Of Acetylamantadine In Urine Samples - Google Patents

Detection And Quantification Of Acetylamantadine In Urine Samples Download PDF

Info

Publication number
US20160041145A1
US20160041145A1 US14/776,702 US201414776702A US2016041145A1 US 20160041145 A1 US20160041145 A1 US 20160041145A1 US 201414776702 A US201414776702 A US 201414776702A US 2016041145 A1 US2016041145 A1 US 2016041145A1
Authority
US
United States
Prior art keywords
acetylamantadine
urine sample
quantification
quantifying
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/776,702
Inventor
Reuven Gordon
Brian Cheng
Rashid Bux
Bram Ramjiawan
Aftab Ahmed
Fraser Alan Hof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomark Technologies Inc
Original Assignee
Biomark Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomark Technologies Inc filed Critical Biomark Technologies Inc
Priority to US14/776,702 priority Critical patent/US20160041145A1/en
Publication of US20160041145A1 publication Critical patent/US20160041145A1/en
Assigned to BIOMARK TECHNOLOGIES INC. reassignment BIOMARK TECHNOLOGIES INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOF, Fraser Alan, RAMJIAWAN, Bram, AHMED, Aftab, CHENG, BRIAN, GORDON, REUVEN, BUX, Rashid
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/02—Investigating particle size or size distribution
    • G01N15/0205—Investigating particle size or size distribution by optical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1434—Optical arrangements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
    • G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
    • G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Definitions

  • the present invention relates to the detection and quantification of biomarkers and, in particular, to the detection and quantification of acetylamantadine in urine samples.
  • Liquid chromatography mass spectrometry has been successfully employed to detect and quantify extremely low concentrations of acetylamantadine in biological samples such as urine. This may facilitate the diagnosis of cancer at an early stage as the quantification of acetylated forms of spermidine/spermine N 1 -acetyltransferase (SSAT) including amantadine may be used to detect various pathological conditions including cancer as disclosed in U.S. Pat. No. 6,811,967 which issued to Sitar et al. on Nov. 4, 2004, and the full disclosure of which is incorporated herein by reference.
  • SSAT acetylated forms of spermidine/spermine N 1 -acetyltransferase
  • the detection and quantification of acetylamantadine using liquid chromatography mass spectrometry is relatively time consuming and costly. There is accordingly a need for an efficient and cost effective method for detecting and quantifying acetylamantadine to allow for rapid economical testing
  • the method comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.
  • the solid phase extraction may include eluting acetylamantadine with methanol.
  • the quantification of the acetylamantadine eluted from the urine sample using Raman spectroscopy may include the use of substrate based, surface-enhanced Raman spectroscopy.
  • the method disclosed herein may be used to screen a patient for a pathological condition based on the quantification of acetylamantadine in the urine sample.
  • the method disclosed herein may also be used to screen a patient for cancer based on the quantification of acetylamantadine in the urine sample.
  • the method disclosed herein may be used to detect and quantify acetylamantadine at a low cost.
  • FIG. 1 shows the results of open air evaporation and slow evaporation of acetylamantadine in a methanol drop coated on a Surface Enhanced Raman Scattering (SERS) substrate;
  • SERS Surface Enhanced Raman Scattering
  • FIG. 2 shows quantification of acetylamantadine using a SERS substrate
  • FIG. 3 shows Raman spectra for different concentrations of acetylamantadine in a methanol
  • FIG. 4 shows a calibration curve based on the Raman spectra of FIG. 3 .
  • acetylamantadine a product of spermidine/spermine N 1 -acetyltransferase (SSAT) metabolism
  • Urine is a concentrated solution of many salts, polar metabolites and multiple non-polar steroids.
  • Expected concentration of acetylamantadine is about 1000 times smaller than that of amantadine in urine samples.
  • the distinction between amantadine and acetylamantadine can be based on the vibrational band of a carbonyl group at an approximately 1600 cm ⁇ 1 wavenumber. There are a few other differences between the spectra of amantadine and acetylamantadine, but this Raman band may be of particular interest as it is present only in the spectrum of acetylamantadine.
  • a urine sample was prepared and different constituents of the urine sample were separated using solid phase extraction (SPE).
  • SPE solid phase extraction
  • the urine sample is accordingly pre-treated using solid phase extraction to remove impurities prior to using Raman spectroscopy to identify and quantify acetylamantadine present in the urine sample.
  • the urine sample was treated using solid phase extraction to remove salts and polar impurities, increase the acetylamantadine to amantadine ratio, and minimize contamination from non-polar steroids.
  • the following protocol achieved all three aims using Strata X, Polymeric Reversed Phase from Phenomenex Inc of 411 Madrid Avenue, Torrance, Calif., 90501-1430.
  • Acetylamantadine in methanol is drop coated on the SERS substrate for Raman measurements.
  • the SERS substrate was a Klarite® SERS substrate from Renishaw Inc. of 5277 Trillium Boulevard, Hoffman Estates, Ill., 60192. Uniform coating of acetylamantadine over the SERS substrate assists in reliable quantification. It was observed that slow evaporation of methanol results in improved coating of acetylamantadine over the substrate.
  • FIG. 1 shows the results of open air evaporation and slow evaporation where the air flow is restricted. It can be seen that slow evaporation results in uniform coating.
  • FIG. 2 shows the quantification based on the 1600 cm ⁇ 1 band. The required resolution and limit of detection of 1 ng/mL is achieved with adequate signal to noise ratio. It will however be understood by a person skilled in the art that it is desirable to use a number of different peaks to create a calibration curve because different peaks will result in result in calibration curves having slightly different slopes.
  • FIG. 3 shows Raman measurements for acetylamantadine in methanol in the following concentrations 1 ng/mL, 5 g/mL, 10 ng/mL, 25 ng/mL and 50 ng/mL which were prepared using standard chemistry techniques to dissolve acetylamantadine in methanol.
  • Five peaks in the Raman spectra were chosen for each concentration, namely, 738 cm ⁇ 1 , 776.8 cm ⁇ 1 , 1198 cm ⁇ 1 , 1210 cm ⁇ 1 and 1436 cm ⁇ 1 .
  • Each peak was separated into a peak area and an adjacent area. Ten points were chosen in each peak area and adjacent area. The points were integrated and the number sum of peak area minus number sum of its adjacent area was used to get the intensity for each peak. It was then possible to get the Raman intensity for each concentration by integrating the five peaks as shown below.
  • I peak is the intensities in peak area and I adjacent is the intensities in adjacent area.
  • I peak is the intensities in peak area and I adjacent is the intensities in adjacent area.
  • the calibration curve may be used to detect and quantify the acetylamantadine in a urine sample.
  • Results demonstrate that acetylamantadine can be extracted from urine samples using solid phase extraction. Raman spectroscopy can then be used to simultaneously detect and quantify the acetylamantadine with a sensitivity of 1 ng/mL in the urine sample to screen a patient for a pathological condition such as cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to the detection and quantification of biomarkers and, in particular, to the detection and quantification of acetylamantadine in urine samples.
  • 2. Description of the Related Art
  • Liquid chromatography mass spectrometry has been successfully employed to detect and quantify extremely low concentrations of acetylamantadine in biological samples such as urine. This may facilitate the diagnosis of cancer at an early stage as the quantification of acetylated forms of spermidine/spermine N1-acetyltransferase (SSAT) including amantadine may be used to detect various pathological conditions including cancer as disclosed in U.S. Pat. No. 6,811,967 which issued to Sitar et al. on Nov. 4, 2004, and the full disclosure of which is incorporated herein by reference. However, the detection and quantification of acetylamantadine using liquid chromatography mass spectrometry is relatively time consuming and costly. There is accordingly a need for an efficient and cost effective method for detecting and quantifying acetylamantadine to allow for rapid economical testing.
    • SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide an improved method for detecting and quantifying acetylamantadine in urine samples.
  • There is accordingly provided a method for quantifying acetylamantadine in a urine sample. The method comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.
  • The solid phase extraction may include eluting acetylamantadine with methanol. The quantification of the acetylamantadine eluted from the urine sample using Raman spectroscopy may include the use of substrate based, surface-enhanced Raman spectroscopy.
  • The method disclosed herein may be used to screen a patient for a pathological condition based on the quantification of acetylamantadine in the urine sample. The method disclosed herein may also be used to screen a patient for cancer based on the quantification of acetylamantadine in the urine sample.
  • The method disclosed herein may be used to detect and quantify acetylamantadine at a low cost.
    • BRIEF DESCRIPTIONS OF DRAWINGS
  • The invention will be more readily understood from the following description of the embodiments thereof given, by way of example only, with reference to the accompanying drawings, in which:
  • FIG. 1 shows the results of open air evaporation and slow evaporation of acetylamantadine in a methanol drop coated on a Surface Enhanced Raman Scattering (SERS) substrate;
  • FIG. 2 shows quantification of acetylamantadine using a SERS substrate;
  • FIG. 3 shows Raman spectra for different concentrations of acetylamantadine in a methanol; and
  • FIG. 4 shows a calibration curve based on the Raman spectra of FIG. 3.
    •  DESCRIPTIONS OF THE PREFERRED EMBODIMENTS
  • Disclosed herein is the use of Raman spectroscopy to identify and quantify acetylamantadine, a product of spermidine/spermine N1-acetyltransferase (SSAT) metabolism, in urine samples. Urine is a concentrated solution of many salts, polar metabolites and multiple non-polar steroids. Expected concentration of acetylamantadine is about 1000 times smaller than that of amantadine in urine samples. The distinction between amantadine and acetylamantadine can be based on the vibrational band of a carbonyl group at an approximately 1600 cm−1 wavenumber. There are a few other differences between the spectra of amantadine and acetylamantadine, but this Raman band may be of particular interest as it is present only in the spectrum of acetylamantadine.
  • A urine sample was prepared and different constituents of the urine sample were separated using solid phase extraction (SPE). The urine sample is accordingly pre-treated using solid phase extraction to remove impurities prior to using Raman spectroscopy to identify and quantify acetylamantadine present in the urine sample.
    • Urine Sample
  • Artificial urine comprising the following components of urine NaCl 8.00 g/L, KCl 1.64 g/L, K2SO4 2.63 g/L, urea 13.40 g/L, and creatinine 1.50 g/L was used to prepare a urine sample having corticosterone 16.7 mM, amantadine 3.3 mM, and acetylamantadine 3.3 uM.
    • Solid Phase Extraction (SPE)
  • The urine sample was treated using solid phase extraction to remove salts and polar impurities, increase the acetylamantadine to amantadine ratio, and minimize contamination from non-polar steroids. The following protocol achieved all three aims using Strata X, Polymeric Reversed Phase from Phenomenex Inc of 411 Madrid Avenue, Torrance, Calif., 90501-1430.
  • (1) Prime: 2 mL MeOH, 2 mL deionized H2O, 2 mL 50 mM pH 7.0 phosphate buffer.
  • (2) Load: Combine 2 mL of urine sample with 2 mL of 50 mM pH 7.0 phosphate buffer and load onto SPE cartridge.
  • (3) Wash 1: 2 mL deionized H2O, 2×1.5 mL 50 mM pH 7.0 phosphate buffer (salts and polar metabolites elute with this fraction).
  • (4) Wash 2: 2×2 mL 40% methanol in H2O2O (amantadine elutes with this fraction while acetylamantadine and the less polar steroid corticosterone is retained).
  • (5) Wash 3: 2 mL 100% methanol (acetylamantadine elutes with this fraction while corticosterone is retained).
  • (6) Dry column by flushing air through it for a few minutes.
  • (7) Eluent: 2 mL ethyl acetate (corticosterone elutes).
    • Coating of acetylamantadine over Surface Enhanced Raman Scattering (SERS) Substrate
  • Acetylamantadine in methanol, obtained from Wash 3 of SPE protocol above, is drop coated on the SERS substrate for Raman measurements. In this example, the SERS substrate was a Klarite® SERS substrate from Renishaw Inc. of 5277 Trillium Boulevard, Hoffman Estates, Ill., 60192. Uniform coating of acetylamantadine over the SERS substrate assists in reliable quantification. It was observed that slow evaporation of methanol results in improved coating of acetylamantadine over the substrate. FIG. 1 shows the results of open air evaporation and slow evaporation where the air flow is restricted. It can be seen that slow evaporation results in uniform coating.
    • Raman Measurements
  • In this example, 30 uL of acetylamantadine in methanol was drop coated on the SERS substrate and allowed to dry slowly. A Raman map of 170 mesh points was collected with 1 second of integration at each mesh point. Out of the 170 spectra, only those were retained which showed Raman peaks, the rest were neglected. FIG. 2 shows the quantification based on the 1600 cm−1 band. The required resolution and limit of detection of 1 ng/mL is achieved with adequate signal to noise ratio. It will however be understood by a person skilled in the art that it is desirable to use a number of different peaks to create a calibration curve because different peaks will result in result in calibration curves having slightly different slopes.
    • Raman Data and Analysis Used to Create a Calibration Curve
  • FIG. 3 shows Raman measurements for acetylamantadine in methanol in the following concentrations 1 ng/mL, 5 g/mL, 10 ng/mL, 25 ng/mL and 50 ng/mL which were prepared using standard chemistry techniques to dissolve acetylamantadine in methanol. Five peaks in the Raman spectra were chosen for each concentration, namely, 738 cm−1, 776.8 cm−1, 1198 cm−1, 1210 cm−1 and 1436 cm−1.
  • Each peak was separated into a peak area and an adjacent area. Ten points were chosen in each peak area and adjacent area. The points were integrated and the number sum of peak area minus number sum of its adjacent area was used to get the intensity for each peak. It was then possible to get the Raman intensity for each concentration by integrating the five peaks as shown below.
  • ∑ n = 5 ( ∑ n_peak = 10 I peak - ∑ n_adjacent = 10 I adjacent )
  • Where Ipeak is the intensities in peak area and Iadjacent is the intensities in adjacent area. The sum of intensities for each concentration were then plotted to create the calibration curves shown in FIG. 4 which also shows the revalidation of the analysis. The calibration curve may be used to detect and quantify the acetylamantadine in a urine sample.
    • Conclusion
  • Results demonstrate that acetylamantadine can be extracted from urine samples using solid phase extraction. Raman spectroscopy can then be used to simultaneously detect and quantify the acetylamantadine with a sensitivity of 1 ng/mL in the urine sample to screen a patient for a pathological condition such as cancer.
  • It will be understood by a person skilled in the art that many of the details provided above are by way of example only, and are not intended to limit the scope of the invention which is to be determined with reference to the following claims.

Claims (6)

1. A method for quantifying acetylamantadine in a urine sample, the method comprising:
eluting acetylamantadine from the urine sample using solid phase extraction; and
quantifying the acetylamantadine eluted from the urine sample using substrate based, surface enhanced Raman spectroscopy.
2. The method as claimed in claim 1 wherein the solid phase extraction includes eluting acetylamantadine with methanol.
3. The method as claimed in claim 1 wherein quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy includes quantifying the acetylamantadine based on a 1600 cm−1 band.
4. The method as claimed in claim 1 wherein quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy includes quantifying the acetylamantadine with a sensitivity of 1 mg/mL.
5. Use of the method as claimed in claim 1 to screen a patient for a pathological condition based on the quantification of acetylamantadine in the urine sample.
6. Use of the method as claimed in claim 1 to screen a patient for cancer based on the quantification of acetylamantadine in the urine sample.
US14/776,702 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples Abandoned US20160041145A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/776,702 US20160041145A1 (en) 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785159P 2013-03-14 2013-03-14
PCT/CA2014/050273 WO2014139025A1 (en) 2013-03-14 2014-03-14 Detection and quantification of acetylamantadine in urine samples
US14/776,702 US20160041145A1 (en) 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2014/050273 A-371-Of-International WO2014139025A1 (en) 2013-03-14 2014-03-14 Detection and quantification of acetylamantadine in urine samples

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/645,994 Continuation US10175226B2 (en) 2013-03-14 2017-07-10 Detection and quantification of acetylamantadine in urine samples

Publications (1)

Publication Number Publication Date
US20160041145A1 true US20160041145A1 (en) 2016-02-11

Family

ID=51535742

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/776,702 Abandoned US20160041145A1 (en) 2013-03-14 2014-03-14 Detection And Quantification Of Acetylamantadine In Urine Samples
US15/645,994 Active US10175226B2 (en) 2013-03-14 2017-07-10 Detection and quantification of acetylamantadine in urine samples

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/645,994 Active US10175226B2 (en) 2013-03-14 2017-07-10 Detection and quantification of acetylamantadine in urine samples

Country Status (5)

Country Link
US (2) US20160041145A1 (en)
EP (1) EP2999964A4 (en)
CN (1) CN105209910B (en)
CA (2) CA2906236C (en)
WO (1) WO2014139025A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3198282A1 (en) * 2015-06-26 2016-12-29 Biomark Cancer Systems Inc. Method of detecting lung cancer
CN106290338B (en) * 2016-09-10 2019-02-22 上海大学 A kind of method for detecting amantadine content
CN110426386A (en) * 2019-09-11 2019-11-08 深圳网联光仪科技有限公司 A kind of Surface enhanced Raman spectroscopy detection pharmaceutical methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439679C (en) * 2001-03-02 2011-07-26 University Of Manitoba Method for assaying non-spermine/spermidine activity of spermidine/spermine n1-acetyltransferase (ssat)
US8102525B2 (en) * 2008-10-07 2012-01-24 OptoTrace (SuZhou) Technologies, Inc. Systems and methods for detecting chemical and biological substances
US20060250613A1 (en) * 2005-04-14 2006-11-09 Chem Image Corporation Method and applications to enhance and image optical signals from biological objects
US7656523B2 (en) * 2006-06-30 2010-02-02 Intel Corporation Multiplexed raman detection with filter set
US20100268473A1 (en) * 2008-02-19 2010-10-21 Tripp Ralph A Methods, devices, and compositions for the highly-sensitive detection and identification of diverse molecular entities
CN102947681B (en) * 2010-04-20 2016-05-18 惠普发展公司，有限责任合伙企业 Strengthen luminous automatic layout, luminous enhance device for surface
US20130040862A1 (en) * 2010-04-20 2013-02-14 Zhiyong Li Multi-pillar structure for molecular analysis
US9410949B2 (en) * 2010-12-03 2016-08-09 Washington University In St. Louis Label-free detection of renal cancer
CN103608358A (en) * 2011-05-10 2014-02-26 百奥马克科技有限公司 Monoclonal antibody for acetylamantadine

Also Published As

Publication number Publication date
CN105209910B (en) 2019-02-15
EP2999964A4 (en) 2017-03-01
CA3212686A1 (en) 2014-09-18
CA2906236A1 (en) 2014-09-18
EP2999964A1 (en) 2016-03-30
US20170328881A1 (en) 2017-11-16
CA2906236C (en) 2023-10-31
WO2014139025A1 (en) 2014-09-18
CN105209910A (en) 2015-12-30
US10175226B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
Golovko et al. Determination of progestogens in surface and waste water using SPE extraction and LC-APCI/APPI-HRPS
Naccarato et al. Development of a simple and rapid solid phase microextraction-gas chromatography–triple quadrupole mass spectrometry method for the analysis of dopamine, serotonin and norepinephrine in human urine
Li et al. Simultaneous determination of clenbuterol, salbutamol and ractopamine in milk by reversed-phase liquid chromatography tandem mass spectrometry with isotope dilution
Hernando et al. Comparative study of analytical methods involving gas chromatography–mass spectrometry after derivatization and gas chromatography–tandem mass spectrometry for the determination of selected endocrine disrupting compounds in wastewaters
Velghe et al. Fully automated therapeutic drug monitoring of anti-epileptic drugs making use of dried blood spots
Dana et al. Rapid analysis of cocaine in saliva by surface-enhanced Raman spectroscopy
Martínez Bueno et al. Occurrence of venlafaxine residues and its metabolites in marine mussels at trace levels: development of analytical method and a monitoring program
Gmeiner et al. Fast screening method for the profile analysis of polycyclic aromatic hydrocarbon metabolites in urine using derivatisation–solid-phase microextraction
US10175226B2 (en) Detection and quantification of acetylamantadine in urine samples
KR101228322B1 (en) Quantitative analytic method for steroid hormones in saliva
Li et al. Reversed-phase liquid chromatography/electrospray ionization/mass spectrometry with isotope dilution for the analysis of nitrate and nitrite in water
Allende et al. LC–MS/MS method for the simultaneous determination of free urinary steroids
Wu et al. Trace analysis of corticosteroids (CSs) in environmental waters by liquid chromatography–tandem mass spectrometry
Ding et al. Simultaneous determination of mono-and disubstituted polyfluoroalkyl phosphates in drinking water by liquid chromatography–electrospray tandem mass spectrometry
CN107144646A (en) A kind of application LC-MS technology combination metabolism group method differentiates the analysis method of true honey and the adulterated honey of syrup
Rivera et al. Influence of natural organic matter on the screening of pharmaceuticals in water by using liquid chromatography with full scan mass spectrometry
Goicoechea et al. Multi-way partial least-squares and residual bi-linearization for the direct determination of monohydroxy-polycyclic aromatic hydrocarbons on octadecyl membranes via room-temperature fluorescence excitation emission matrices
Camino-Sánchez et al. Validation of a method for the determination of tributyltin in seawater by stir bar sorptive extraction–liquid chromatography tandem mass spectrometry
CN104965042A (en) Detection method for various kinds of trace glucocorticoid and derivate thereof in surface water body
Pan et al. Comparison of different calibration approaches for chloramphenicol quantification in chicken muscle by ultra-high pressure liquid chromatography tandem mass spectrometry
Bermudo et al. Field amplified sample injection–capillary electrophoresis–tandem mass spectrometry for the analysis of acrylamide in foodstuffs
Bouzidi et al. Determination of total sterols in brown algae by Fourier transform infrared spectroscopy
Alfarhani et al. Room temperature fluorescence spectroscopy of benzo [a] pyrene metabolites on octadecyl extraction membranes
CN107192770A (en) A kind of analysis method for differentiating chaste honey and the adulterated chaste honey of syrup
Yasuhara et al. Automated analysis of salivary stress-related steroid hormones by online in-tube solid-phase microextraction coupled with liquid chromatography-tandem mass spectrometry

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIOMARK TECHNOLOGIES INC., CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GORDON, REUVEN;CHENG, BRIAN;BUX, RASHID;AND OTHERS;SIGNING DATES FROM 20130326 TO 20130410;REEL/FRAME:043817/0751